Trident Texofab Intrinsic Value
Trident Texofab (TTFL) median intrinsic value is ₹20.00 from 8 valuation models (range ₹7–₹46), vs current price ₹23.07 — -13.3% downside (Trading Above Median Value), margin of safety -15.4%. For current market price and key ratios, visit TTFL share price.
TTFL Valuation Methods Summary — DCF, Graham Number & P/E
Trident Texofab intrinsic value across 8 models vs current price ₹23.07 — upside/downside and value range per method. Check Trident Texofab market worth to track the company's total market size over time.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹6.92 | ₹5.54 - ₹8.30 | -70.0% | EPS: ₹0.20, Sector P/E: 12x |
| Book Value Method | asset | ₹37.33 | ₹33.60 - ₹41.06 | +61.8% | Book Value/Share: ₹37.33, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹46.14 | ₹41.53 - ₹50.75 | +100.0% | Revenue/Share: ₹78.67, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹20.00 | ₹18.00 - ₹22.00 | -13.3% | EBITDA: ₹5.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹26.64 | ₹21.31 - ₹31.97 | +15.5% | CF Growth: 14.5%, Discount: 15% |
| PEG Ratio Method | growth | ₹6.92 | ₹6.23 - ₹7.61 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹6.92 | ₹6.23 - ₹7.61 | -70.0% | Revenue Growth: 4.8%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹12.96 | ₹11.66 - ₹14.26 | -43.8% | EPS: ₹0.20, BVPS: ₹37.33 |
TTFL Intrinsic Value vs Market Price — All Valuation Models
Trident Texofab fair value range ₹7–₹46 vs current market price ₹23.07 across 8 valuation models. See TTFL P/B ratio to compare market price against book value per share.
TTFL Intrinsic Value Analysis — Undervalued or Overvalued?
Trident Texofab median intrinsic value ₹20.00, current price ₹23.07 — Trading Above Median Value by 13.3%, margin of safety -15.4%.
What is the intrinsic value of TTFL?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Trident Texofab (TTFL) is ₹20.00 (median value). With the current market price of ₹23.07, this represents a -13.3% variance from our estimated fair value.
The valuation range spans from ₹6.92 to ₹46.14, indicating ₹6.92 - ₹46.14.
Is TTFL undervalued or overvalued?
Based on our multi-method analysis, Trident Texofab (TTFL) appears to be trading above median value by approximately 13.3%.
TTFL Financial Health — Key Ratios vs Industry Benchmarks
Trident Texofab financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 4.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.06x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
TTFL Cash Flow Quality — Operating & Free Cash Flow
Trident Texofab operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-24 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹6 Cr | ₹6 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹2 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |